(PLUN) ProstaLund - Ratings and Ratios
Exchange: ST • Country: Sweden • Currency: SEK • Type: Common Stock • ISIN: SE0002372318
PLUN: CoreTherm, CoreFlow, Oruflow, Dosi-Fuser, Dosi-Flow, Schelin Catheter
ProstaLund AB (publ), a medical technology company specializing in urological solutions, develops, manufactures, and distributes innovative devices and treatments for urological conditions. Its product portfolio includes CoreTherm, a minimally invasive heat treatment for benign prostatic hyperplasia (BPH); CoreFlow, a soft stent designed to improve urine flow; Oruflow, a urine flow meter for diagnostic purposes; Dosi-Fuser, a disposable continuous infusion system; and Dosi-Head, a gravitational flow regulator for precise medication dosing. The company also offers the Schelin Catheter, a sterile injection tool for prostate drug delivery. These products are primarily used in hospitals and clinics, addressing both diagnostic and therapeutic needs in urology. Established in 1991 and headquartered in Lund, Sweden, ProstaLund AB operates as a subsidiary of Farstorps Gard Forvaltnings AB, focusing on improving patient outcomes through advanced urological care.
From a technical perspective, ProstaLund ABs stock (Ticker: PLUN) on the Stockholm Stock Exchange exhibits a bearish trend, with its last price of 5.80 SEK below its SMA 20 (7.04), SMA 50 (8.17), and SMA 200 (13.66) levels. This indicates a downward momentum over the past year. The Average True Range (ATR) of 0.98 suggests moderate volatility. Fundamentally, the company has a market capitalization of 21.02M SEK, with a price-to-book (P/B) ratio of 0.36, indicating undervaluation relative to book value. However, the negative return on equity (RoE) of -41.01% highlights profitability challenges. The price-to-sales (P/S) ratio of 1.53 reflects a premium valuation relative to revenue.
3-month forecast: Based on technical and fundamental data, PLUN is expected to remain under pressure, with potential resistance at SMA 50 (8.17) and support near the SMA 200 (13.66). The stock may experience slight rebounds but is likely to maintain its downward trajectory due to weak momentum and negative profitability trends. Investors should monitor earnings reports and operational updates for potential catalysts.
Additional Sources for PLUN Stock
PLUN Stock Overview
| Market Cap in USD | 2m |
| Sector | Healthcare |
| Industry | Medical Care Facilities |
| GiC Sub-Industry | Health Care Services |
| IPO / Inception |
PLUN Stock Ratings
| Growth 5y | -85.8% |
| Fundamental | -39.3% |
| Dividend | 0.0% |
| Rel. Strength Industry | -87.8 |
| Analysts | - |
| Fair Price Momentum | 4.22 SEK |
| Fair Price DCF | - |
PLUN Dividends
No Dividends PaidPLUN Growth Ratios
| Growth Correlation 3m | -73.4% |
| Growth Correlation 12m | -98.2% |
| Growth Correlation 5y | -60.7% |
| CAGR 5y | -36.91% |
| CAGR/Max DD 5y | -0.38 |
| Sharpe Ratio 12m | -1.12 |
| Alpha | -92.39 |
| Beta | -0.05 |
| Volatility | 121.36% |
| Current Volume | 22k |
| Average Volume 20d | 6k |
As of March 15, 2025, the stock is trading at SEK 5.30 with a total of 21,987 shares traded.
Over the past week, the price has changed by -8.62%, over one month by -42.70%, over three months by -42.39% and over the past year by -87.69%.
Probably not. Based on ValueRay Fundamental Analyses, ProstaLund (ST:PLUN) is currently (March 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -39.30 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of PLUN as of March 2025 is 4.22. This means that PLUN is currently overvalued and has a potential downside of -20.38%.
ProstaLund has no consensus analysts rating.
According to ValueRays Forecast Model, PLUN ProstaLund will be worth about 4.6 in March 2026. The stock is currently trading at 5.30. This means that the stock has a potential downside of -13.96%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 4.6 | -14% |